Efffect of recombinant human FSH on ovulation, pregnancy and in vitro fertilization in androgen-sterilized mice.
The effect of a new rhFSH, PG-0801, on oocyte quality, ovulation and in vitro fertilization (IVF) was examined in androgen-sterilized mice. Experimental sterility was induced by a single subcutaneous injection of testosterone propionate (TP, 1 mg/head) into 5 day old female mice. Ovulation was generated in the 10 to 13-week old TP-injected mice by a subcutaneous rhFSH injection (1, 5 or 10 IU/head) followed 48 hours later by a second rhFSH injection (1, 5 or 10 IU/head). For comparison, a subcutaneous PMSG (5 IU/head) injection was used for folliculogenesis and a hCG (5 IU/head) injection was used for ovulation. These were administered using the same protocol. The eggs were harvested from the oviducts and counted 17 to 20 hours after the second injection. IVF was performed by adding sperms (2 x 10(5)/ml to 2 x 106/ ml) to determine the functional activity of the eggs, and the fertilization rate was measured. In addition, the pregnancy rate and fetal development were examined after 15-17 days of gestation. The number of oocytes recovered from the rhFSH/rhFSH group increased dose-dependently and was slightly higher than that of the PMSG/hCG group. The pregnancy rates of the group receiving 1, 5, and 10 IU of rhFSH/rhFSH were 50%, 66.7%, and 75%, respectively, which were significantly higher than that of the control (untreated) group (0%). The numbers of viable fetuses in the 1, 5, and 10 IU/head of the rhFSH/rhFSH group (8.0 +/- 1.50, 8.9 +/- 1.02, and 8.9 +/- 1.12 fetuses/dam, respectively) were comparable to that of the 5 IU/head PMSG/ hCG group (9.4 +/- 0.94). The mice receiving rhFSH/rhFSH and PMSG/hCG showed similar fertilization rates (around 65%) via the IVF procedure. These results demonstrate that a new rhFSH, PG-0801, may be useful for inducing ovulation in functionally infertile patients and for superovulation in ovulatory patients participating in assisted reproductive technology (ART) programs.
Research Laboratories, Dong-A Pharm Co Ltd, Yongin, Kyunggi, Korea.
Sang Bum
SB
Koh
Kwang Suk
KS
Seo
Seung-Chul
SC
Kim
Byoung Ok
BO
Ahn
Won Bae
WB
Kim
Sung Hee
SH
Lee
D000728:Androgens / Q000494:pharmacology*; D000818:Animals; D005260:Female; D005307:Fertilization in Vitro; D005640:Follicle Stimulating Hormone / Q000494:pharmacology*; D006801:Humans; D007247:Infertility, Female / Q000139:chemically induced* / Q000517:prevention & control*; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D009865:Oocytes / Q000187:drug effects; D010060:Ovulation / Q000187:drug effects*; D011247:Pregnancy; D011270:Pregnancy, Animal / Q000187:drug effects*; D011994:Recombinant Proteins / Q000494:pharmacology; D012726:Sexual Behavior, Animal / Q000187:drug effects
D000728:Androgens; D011994:Recombinant Proteins; D005640:Follicle Stimulating Hormone